Linked Life Data

15919438

Source:http://linkedlifedata.com/resource/pubmed/id/15919438

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-5-27
pubmed:abstractText
Recurrent hepatitis C virus (HCV) infection is universal after liver transplantation (LT), yet no effective therapy is available. Amantadine (Am) is currently under evaluation. The aim of this study was to assess the safety and the effectiveness of Am monotherapy in LT patients with HCV recurrence.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0041-1345
pubmed:author
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1705-7
pubmed:dateRevised
2007-9-21
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting.
pubmed:affiliation
Liver Transplant Unit, Tor Vergata University of Rome, Surgical Clinic, S. Eugenio Hospital, Rome, Italy.
pubmed:publicationType
Journal Article